ArticleAnnals of surgical oncology2026
Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2- Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Does Ki67 Gene Expression Capture Immune Infiltration and Predict Chemotherapy Response in ER+/HER2- Breast Cancer?Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundKi67 is one of the most widely used markers of cell proliferation. However, current measurements using immunohistochemistry (IHC) are limited by interobserver variability and lack of standardized cutoffs. To address this, we investigated the association of Ki67 gene (MKI67) expression with biological features and treatment response in estrogen receptor-positive (ER+) breast cancer (BC), the most common subtype. PATIENTS AND
methodsWe analyzed 5036 patients with ER+/HER2- BC across 11 independent cohorts with tumor transcriptomes and clinical data. Patients with MKI67 expression in the top 20% were defined as the high-expression group on the basis of prior IHC-based thresholds.
resultsMKI67 expression correlated with Nottingham histologic grade and proliferation score, and consistently enriched all the hallmark cell proliferation-related gene sets across TCGA, METABRIC, and SCAN-B cohorts. High MKI67 expression trended toward worse survival but achieved statistical significance only in the METABRIC cohort. MKI67 high ER+/HER2- BC was associated with increased mutation rates, fraction altered, homologous recombination deficiency and intratumoral genomic heterogeneity. MKI67 expression was associated with infiltration of Th1 and Th2 cells as well as M1 and M2 macrophages across three cohorts. Conversely, MKI67 low ER+/HER2- BC was enriched for Hypoxia, Coagulation, Epithelial-to-Mesenchymal Transition, NOTCH, Hedgehog, TGF-beta, and KRAS-signaling gene sets. MKI67 high ER+/HER2- BC was associated with a higher pathological complete response (pCR) rate in four of the eight neoadjuvant chemotherapy cohorts.
conclusionsHigh MKI67 expression identifies highly proliferative tumors that are associated with genomic instability and immune activity and is associated with higher pCR rates following neoadjuvant chemotherapy in ER+/HER2- BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.